Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor Inhibitors

• Hoofdauteurs: Jessica A. Walsh (Auteur), Iris Lin (Auteur), Ruizhi Zhao (Auteur), Natalie J. Shiff (Auteur), Laura Morrison (Auteur), Bruno Emond (Auteur), Louise H. Yu (Auteur), Samuel Schwartzbein (Auteur), Patrick Lefebvre (Auteur), Dominic Pilon (Auteur), Soumya D. Chakravarty (Auteur), Philip Mease (Auteur)
• Formaat: Boek
• Gepubliceerd in: Adis, Springer Healthcare, 2024-07-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Abstract Background Treatment persistence among patients with psoriatic arthritis (PsA) is essential for achieving optimal treatment outcomes. Guselkumab, a fully human interleukin-23p19-subunit inhibitor, was approved by the United States (US) Food and Drug Administration for the treatment of activ...